Solid Biosciences congratulates Sarepta on the U.S. approval of the first therapy for Duchenne muscular dystrophy.
Solid was proud to sponsor the 8th Annual Gals For Cal team at the recent Max Performance Title 9 Triathlon at Hopkinton State Park in Massachusetts.
“We are fighters and we want what’s right and best ... We only have one problem, it’s called Duchenne.”
—Padraik and Paula
“Think about what you can do rather than what you can’t do. It can be devastating to find out you have Duchenne. But there’s still a lot of life to live.”
Solid Biosciences joined the Jett Foundation and other members of the local Cambridge, MA community to observe World Duchenne Awareness Day.
Solid Biosciences Community Update Q2 2016
Grants from the charities Duchenne Now, Save Our Sons and Fight DMD will support important work in furthering Solid’s gene therapy and disease modifying therapy programs.
The biologic candidate LTBP4 has the potential to promote muscle health and reduce fibrosis in patients with Duchenne muscular dystrophy.
Carl Morris, Solid Biosciences’ vice president of Research and Development, speaks about being a “Game Changer in Rare Disease.”
Exciting new preclinical data at the world’s foremost gene therapy conference shows the potential of Solid GT’s AAV micro-dystrophin gene replacement candidate in Duchenne muscular dystrophy (DMD).
Please subscribe to receive our latest news